Skip to main content

Advertisement

SpringerLink
Log in

A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Background

Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS).

Objective

To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) people with MS (pwMS).

Methods

Multicenter study. RR pwMS on first-line DMTs completed Fatigue Severity Scale (FSS), PROs Indices for MS (PRIMUS), 36-item Short-Form Health Survey (SF-36), treatment satisfaction questionnaire for medication (TSQM), Beck Depression Inventory-II (BDI-II), and Symbol Digit Modalities Test (SDMT). Differences among PROs across DMTs were tested by ANOVA. Multivariable linear regressions were used to investigate associations between PROs and the treatment group.

Results

Two-hundred eighty pwMS were enrolled: 56% were on interferons (INF), 22% on dimethylfumarate (DMF), 13% on glatiramer acetate, and 9% on teriflunomide (Teri). Compared with INF, pwMS on Teri were the oldest, with higher disability, worst depression at BDI, worst cognitive performances at SDMT (p = 0.001), fatigue at FSS (p = 0.001), and activity limitation and quality of life respectively at PRIMUS (p = 0.005) and SF-36 Mental Composite Score (p < 0.001); pwMS on DMF reported highest side effects and, together with pwMS on Teri, better treatment satisfaction at TSQM.

Conclusions

Compared with INF-treated patients, pwMS on DMF and Teri reported the best treatment satisfaction, although DMF-treated pwMS reported higher side effects and those on Teri the worst QoL and fatigue; however, the older age, higher disability and depression, and worse cognitive performance of pwMS on Teri suggest to be careful in evaluating these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, la Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP, iMUST group. (2017) Assessing association of comorbidities with treatment choice and persistence in MS: a real-life multicenter study. Neurology 89: 2222–2229

  2. D’Amico E, Leone C, Caserta C et al (2015) Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev Neurother 15:803–824

    Article  Google Scholar 

  3. Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C, R.I.Re.MS study group. (2018) R.I.Re.MS study group. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. J Neurol 265(5):1174–1183

  4. Havrdova E, Galetta S, Stefoski D et al (2010) Freedom from disease activity in multiple sclerosis. Neurology 74(Suppl. 3):S3–S7

    Article  Google Scholar 

  5. US Department of Health and Human Services Food and Drug Administration, FDA (2009). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims

  6. Speight J, Barendse SM (2010) FDA guidance on patient reported outcomes. BMJ 340:c292

    Article  Google Scholar 

  7. Giovannoni G, Tomic D, Bright JR et al (2017) “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23(9):1179–1187

    Article  Google Scholar 

  8. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483

    Article  Google Scholar 

  9. Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ (2009) The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler 15(9):1092–1102

    Article  CAS  Google Scholar 

  10. Atkinson MJ, Sinha A, Hass SL et al (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12

    Article  Google Scholar 

  11. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123

    Article  CAS  Google Scholar 

  12. Beck AT, Steer RA, Brown GA (1996) Beck Depression Inventory-II (BDI-II) manual. Pearson, Oxford, England

    Google Scholar 

  13. Learmonth YC, Motl RW, Sandroff BM et al (2013) Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 13:37

    Article  Google Scholar 

  14. Lavorgna L, Sparaco M, Esposito S, Motl RW, Gallo A, Bisecco A, Tedeschi G, Bonavita S (2017) Validity and reproducibility of the Italian version of the patient determined disease steps scale in people with multiple sclerosis. Mult Scler Relat Disord 18:173–176

    Article  Google Scholar 

  15. Lavorgna L, Miele G, Petruzzo M, Lanzillo R, Bonavita S (2018) Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis. Mult Scler Relat Disord. 21:108–109

    Article  CAS  Google Scholar 

  16. Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, Ciccarelli O (2018) Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol 14(2):75–93

    Article  Google Scholar 

  17. Benedict, R.H., DeLuca, J., Phillips, G., LaRocca N., Hudson L.D., Rudick R., Multiple Sclerosis Outcome Assessments Consortium. (2017) Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 23(5): 721–733

  18. Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L (2014) Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther 36(12):1958–1971

    Article  CAS  Google Scholar 

  19. Saccà F, Lanzillo R, Signori A, et al. (2018) On behalf of the iMUST group. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: a real-life study. Mult Scler 1352458518790390

  20. Coyle PK, Khatri B, Edwards KR et al (2018) Teri-PRO trial group. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: results from the global phase 4 Teri-PRO study in routine clinical practice. Mult Scler Relat Disord. 26:211–218

    Article  Google Scholar 

  21. Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51(11):1025–1036

    Article  CAS  Google Scholar 

  22. Condé S, Moisset X, Pereira B, Zuel M, Colamarino R, Maillet-Vioud M, Lauxerois M, Taithe F, Clavelou P, Réseau NeuroSEP Auvergne. (2018) Dimethyl-fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study. Eur J Neurol 26(3):460–467

Download references

Author information

Author notes

  1. R. Lanzillo and M. Sparaco contributed equally to the manuscript.

Authors and Affiliations

  1. Multiple Sclerosis Center, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy

    R. Lanzillo, T. Costabile, F. Saccà, C. V. Russo, N. Frattaruolo, A. Strianese & V. Brescia Morra

  2. Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy

    M. Sparaco, L. Lavorgna, E. Signoriello, S. Cepparulo, A. Bisecco, G. Lus & S. Bonavita

  3. Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, Italy

    L. Carmisciano & A. Signori

  4. MS Centre, Neurology Unit, Cardarelli Hospital, Naples, Italy

    G. T. Maniscalco

Authors
  1. R. Lanzillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Sparaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Lavorgna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Carmisciano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Signoriello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Signori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Costabile
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. T. Maniscalco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Saccà
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Cepparulo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C. V. Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A. Bisecco
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N. Frattaruolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Strianese
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G. Lus
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. V. Brescia Morra
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. S. Bonavita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Bonavita.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was approved by the ethics committee of the coordinating center (University of Campania “Luigi Vanvitelli”) while the local ethics committees at all centers assented to the raw data collection.

Signed informed consent was obtained from each patient prior to enrollment in the study according to the Declaration of Helsinki.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 21 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lanzillo, R., Sparaco, M., Lavorgna, L. et al. A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. Neurol Sci 41, 3235–3241 (2020). https://doi.org/10.1007/s10072-020-04367-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-020-04367-9

Keywords

Search

Navigation